Covaxin Booster dose Effectiveness against COVID-19 infection in Adult Populatio
- Registration Number
- CTRI/2022/06/043197
- Lead Sponsor
- Bharat Biotech International Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Adults aged 18 years and older who have received at least 2 primary doses of COVAXIN�® 9 months prior to enrolment or third dose (booster or precautionary dose) of COVAXIN�® within 6month prior to enrolment.
The subject should have received third dose at least 14 days before he/she is enrolled in the study.
Individuals with stable pre-existing medical conditions such as hypertension, diabetes, obesity, cardiovascular disease, respiratory disorders, liver disease or any other stable chronic disorders).
Intention of being available for entire study period
Population aged below 18 years
Subjects with chronic illness, disorder, or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint.
Subjects with psychiatric disorders
Subject who has taken COVID vaccine other than COVAXIN�®
Subject who has received single dose of COVAXIN�®
Subjects who cannot provide written consent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method